These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 30885703)

  • 1. FOB vs modified Irwin: What are we doing?
    Gauvin DV; Zimmermann ZJ
    J Pharmacol Toxicol Methods; 2019; 97():24-28. PubMed ID: 30885703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The functional observational battery and modified Irwin test as global neurobehavioral assessments in the rat: Pharmacological validation data and a comparison of methods.
    Redfern WS; Dymond A; Strang I; Storey S; Grant C; Marks L; Barnard C; Heys C; Moyser K; Greenwood K; Cobey D; Moore N; Karp NA; Prior H
    J Pharmacol Toxicol Methods; 2019; 98():106591. PubMed ID: 31146025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Irwin Test and Functional Observational Battery (FOB) for Assessing the Effects of Compounds on Behavior, Physiology, and Safety Pharmacology in Rodents.
    Mathiasen JR; Moser VC
    Curr Protoc Pharmacol; 2018 Dec; 83(1):e43. PubMed ID: 30179315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CNS Adverse Effects: From Functional Observation Battery/Irwin Tests to Electrophysiology.
    Fonck C; Easter A; Pietras MR; Bialecki RA
    Handb Exp Pharmacol; 2015; 229():83-113. PubMed ID: 26091637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CNS Safety Screening Under ICH S7A Guidelines Requires Observations of Multiple Behavioral Units to Assess Motor Function.
    Gauvin DV; Zimmermann ZJ; Dalton JA; Baird TJ; Kallman MJ
    Int J Toxicol; 2019; 38(5):339-356. PubMed ID: 31470748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The standardized functional observational battery: Its intrinsic value remains in the instrument of measure: The rat.
    Gauvin DV; Yoder JD; Holdsworth DL; Harter ML; May JR; Cotey N; Dalton JA; Baird TJ
    J Pharmacol Toxicol Methods; 2016; 82():90-108. PubMed ID: 27534836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Variability of non-clinical behavioral CNS safety assessment: An intercompany comparison.
    Himmel HM; ; Delaunois A; Deurinck M; Dinklo T; Eriksson Faelker TM; Habermann C; Heers C; Hempel K; Lorenz H; Rosch A; Schauerte H; Teuns G; Traebert M; van Amsterdam C; van der Linde H
    J Pharmacol Toxicol Methods; 2019; 99():106571. PubMed ID: 30928509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repeated "Day 1" FOB testing in ICH S7A safety assessment protocols: The influence of within- and between-session learning.
    Gauvin DV; Zimmermann ZJ; Dalton JA; Baird TJ
    J Pharmacol Toxicol Methods; 2017; 85():61-72. PubMed ID: 28216425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. De-risking in Tier I CNS safety assessments is the primary function of study design and technical training of laboratory staff observers.
    Gauvin DV; Zimmermann ZJ; Dalton JA
    Regul Toxicol Pharmacol; 2022 Mar; 129():105116. PubMed ID: 35017023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurofunctional test batteries in safety pharmacology - Current and emerging considerations for the drug development process.
    Jackson SJ; Authier S; Brohmann H; Goody SMG; Jones D; Prior H; Rosch A; Traebert M; Tse K; Valentin JP; Milne A
    J Pharmacol Toxicol Methods; 2019; 100():106602. PubMed ID: 31238094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simultaneous assessment of central nervous and respiratory systems using jacketed telemetry in socially-housed rats: Application of the "3Rs" principles in core battery safety pharmacology studies.
    Fares R; Champéroux P
    J Pharmacol Toxicol Methods; 2023; 121():107268. PubMed ID: 37146838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benchmarking safety pharmacology regulatory packages and best practice.
    Lindgren S; Bass AS; Briscoe R; Bruse K; Friedrichs GS; Kallman MJ; Markgraf C; Patmore L; Pugsley MK
    J Pharmacol Toxicol Methods; 2008; 58(2):99-109. PubMed ID: 18692579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spectrum of effects detected in the rat functional observational battery following oral administration of non-CNS targeted compounds.
    Redfern WS; Strang I; Storey S; Heys C; Barnard C; Lawton K; Hammond TG; Valentin JP
    J Pharmacol Toxicol Methods; 2005; 52(1):77-82. PubMed ID: 15936219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of neurotoxicity potential in rats: the functional observational battery.
    Boucard A; Bétat AM; Forster R; Simonnard A; Froget G
    Curr Protoc Pharmacol; 2010 Dec; Chapter 10():Unit 10.12. PubMed ID: 21935896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing the predictive value of the rodent neurofunctional assessment for commonly reported adverse events in phase I clinical trials.
    Mead AN; Amouzadeh HR; Chapman K; Ewart L; Giarola A; Jackson SJ; Jarvis P; Jordaan P; Redfern W; Traebert M; Valentin JP; Vargas HM
    Regul Toxicol Pharmacol; 2016 Oct; 80():348-57. PubMed ID: 27155597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a Functional Observational Battery in the Minipig for Regulatory Neurotoxicity Assessments.
    Zhong M; Shoemake C; Fuller A; White D; Hanks C; Brocksmith D; Liu J; Gad S; Bouchard G; Stricker-Krongrad A
    Int J Toxicol; 2017; 36(2):113-123. PubMed ID: 28196426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary observation (Irwin) test in rodents for assessing acute toxicity of a test agent and its effects on behavior and physiological function.
    Roux S; Sablé E; Porsolt RD
    Curr Protoc Pharmacol; 2005 Jan; Chapter 10():Unit 10.10. PubMed ID: 22294127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Core battery safety pharmacology testing - An assessment of its utility in early drug development.
    Baldrick P
    J Pharmacol Toxicol Methods; 2021; 109():107055. PubMed ID: 33813006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relative equivalence of CNS safety (FOB) assessment outcomes in male and female Wistar-Han and Sprague-Dawley rats.
    Gauvin DV; Dalton JA; Harter ML; Holdsworth D; May J; Tapp R; Zimmermann ZJ; Kilgus Q; Baird TJ
    J Pharmacol Toxicol Methods; 2019; 95():2-11. PubMed ID: 30476622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multi-site comparison of in vivo safety pharmacology studies conducted to support ICH S7A & B regulatory submissions.
    Ewart L; Milne A; Adkins D; Benjamin A; Bialecki R; Chen Y; Ericsson AC; Gardner S; Grant C; Lengel D; Lindgren S; Lowing S; Marks L; Moors J; Oldman K; Pietras M; Prior H; Punton J; Redfern WS; Salmond R; Skinner M; Some M; Stanton A; Swedberg M; Finch J; Valentin JP
    J Pharmacol Toxicol Methods; 2013; 68(1):30-43. PubMed ID: 23665080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.